Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

APPROVED_FOR_MARKETING

Conditions studied: Superoxide Dismutase 1-Amyotropic Lateral Sclerosis

In brief

The objective of this early access program (EAP) is to provide access to tofersen to eligible participants with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene prior to an alternative access mechanism in order to address a high unmet medical need in this population.

Key facts

Study ID

NCT04972487

Run by

Biogen

Last updated by the study team

2024-06-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Anchorage, Alaska, United States
• Research Site — Los Angeles, California, United States
• Research Site — Orange, California, United States
• Research Site — San Diego, California, United States
• Research Site — San Francisco, California, United States
• Research Site — Chicago, Illinois, United States
• Research Site — Kansas City, Kansas, United States
• Research Site — Boston, Massachusetts, United States
• Research Site — Worcester, Massachusetts, United States
• Research Site — Ann Arbor, Michigan, United States
• Research Site — Detroit, Michigan, United States
• Research Site — Rochester, Minnesota, United States
• Research Site — St Louis, Missouri, United States
• Research Site — Lebanon, New Hampshire, United States
• Research Site — Amherst, New York, United States
• Research Site — New York, New York, United States
• Research Site — Syracuse, New York, United States
• Research Site — Philadelphia, Pennsylvania, United States
• Research Site — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.